We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lotus Pharmaceuticals Inc (PK) | USOTC:LTUS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0029 | 0.0008 | 0.0038 | 0.00 | 11:46:43 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-32581
LOTUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Nevada |
|
20-0507918 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
16 Cheng Zhuang Road, Feng Tai District, Beijing 100071
People’s Republic of China
86-10-63899868
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, par value $0.001
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1) |
x |
Rule 15d-6 |
o |
|
|
|
|
Rule 12g-4(a)(2) |
o |
|
|
|
|
|
|
Rule 12h-3(b)(1)(i) |
o |
|
|
|
|
|
|
Rule 12h-3(b)(1)(i)(ii) |
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate number of holders of record as of the certification or notice date: |
77 |
Pursuant to the requirements of the Securities Exchange Act of 1934, Lotus Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
DATE: |
May 11, 2012 |
|
By: |
/s/ Liu Zhongyi |
|
|
|
|
Liu Zhongyi |
|
|
|
|
Chief Executive Officer |
1 Year Lotus Pharmaceuticals (PK) Chart |
1 Month Lotus Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions